- Home
- CRGX vs ALT Comparison
CRGX vs ALT Comparison
Compare CRGX & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRGX
- ALT
- Stock Information
- Founded
- CRGX 2021
- ALT 1997
- Country
- CRGX United States
- ALT United States
- Employees
- CRGX N/A
- ALT N/A
- Industry
- CRGX
- ALT Biotechnology: Pharmaceutical Preparations
- Sector
- CRGX
- ALT Health Care
- Exchange
- CRGX Nasdaq
- ALT Nasdaq
- Market Cap
- CRGX 621.4M
- ALT 529.9M
- IPO Year
- CRGX 2023
- ALT N/A
- Fundamental
- Price
- CRGX $12.39
- ALT $6.86
- Analyst Decision
- CRGX Strong Buy
- ALT Strong Buy
- Analyst Count
- CRGX 6
- ALT 8
- Target Price
- CRGX $31.80
- ALT $19.71
- AVG Volume (30 Days)
- CRGX 287.3K
- ALT 2.7M
- Earning Date
- CRGX 11-12-2024
- ALT 11-12-2024
- Dividend Yield
- CRGX N/A
- ALT N/A
- EPS Growth
- CRGX N/A
- ALT N/A
- EPS
- CRGX N/A
- ALT N/A
- Revenue
- CRGX N/A
- ALT $52,000.00
- Revenue This Year
- CRGX N/A
- ALT N/A
- Revenue Next Year
- CRGX N/A
- ALT N/A
- P/E Ratio
- CRGX N/A
- ALT N/A
- Revenue Growth
- CRGX N/A
- ALT N/A
- 52 Week Low
- CRGX $10.91
- ALT $5.28
- 52 Week High
- CRGX $33.92
- ALT $14.84
- Technical
- Relative Strength Index (RSI)
- CRGX 39.66
- ALT 41.92
- Support Level
- CRGX $10.91
- ALT $6.19
- Resistance Level
- CRGX $15.75
- ALT $7.83
- Average True Range (ATR)
- CRGX 1.20
- ALT 0.41
- MACD
- CRGX -0.11
- ALT -0.06
- Stochastic Oscillator
- CRGX 30.08
- ALT 36.41
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platform technologies, and manufacturing plan are designed to directly address the key limitations of approved cell therapies, including limited durability of effect, suboptimal safety and unreliable supply. The company's program, CRG-022, is a novel CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in a vast majority of B-cell malignancies.
About ALT Altimmune Inc.
Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company's pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.